Health, Benzinga, Biotechnology, Business, Finance

Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2

October 28, 2021 No Comments

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated […]

Business, Benzinga, Biotechnology, Finance, Health

What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

September 8, 2021 No Comments

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward. According to Statera, preclinical testing is underway in the […]

Health, Benzinga, Biotechnology, Business, Finance

Statera BioPharma: The Ticker Formerly Known as CBLI

September 7, 2021 No Comments

Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. On September 1, 2021, Cytocom officially became listed as Statera BioPharma, Inc. (NASDAQ: STAB), as it updated its ticker symbol from CLBI to STAB within the Nasdaq markets. This change in name comes as a natural progression, as the company shifts gears toward placing a more strategic focus on restoring total […]